Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion

Cancer

Volumn 118, Issue 13, 2012, Pages 3302-3310

  Kasai, Kazuhiro ^a   Ushio, Akira ^a   Kasai, Yukiho ^a   Sawara, Kei ^a   Miyamoto, Yasuhiro ^a   Oikawa, Kanta ^a   Kuroda, Hidekatsu ^a   Takikawa, Yasuhiro ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Pegylated interferon 2b; Portal venous invasion

Indexed keywords

CISPLATIN; FLUOROURACIL; PEGINTERFERON ALPHA2B;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURGERY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; FATIGUE; FEMALE; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN TUMOR THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR THROMBUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PORTAL VEIN; PROGNOSIS; RECOMBINANT PROTEINS; SURVIVAL RATE; VENOUS THROMBOSIS;

EID: 84862558130     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26648     Document Type: Article

References (44)

1. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999; 29: 62-67. (Pubitemid 29023987)
2. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56: 918-928. (Pubitemid 15228292)
3. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J,. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005; 100: 1995-2004.
4. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655. (Pubitemid 13149996)
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
7. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009; 115: 428-436.
8. Iwamiya T, Sawada S, Ohta Y,. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol. 1994; 33 (suppl): S134-S138. (Pubitemid 24147983)
9. Une Y, Uchino J, Yasuhara M, et al. Intra-arterial infusion chemotherapy on unresectable hepatocellular carcinoma under occlusion of hepatic arterial flow. Clin Ther. 1993; 15: 347-354. (Pubitemid 23168498)
10. Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006; 106: 1990-1997. (Pubitemid 43673215)
11. Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002; 94: 435-442. (Pubitemid 34081374)
12. Delgado C, Francis GE, Fisher D,. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst. 1992; 9: 249-304.
13. Inada Y, Furukawa M, Sasaki H, et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 1995; 13: 86-91.
14. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000; 68: 556-567.
15. Kasai K, Kuroda H, Ushio A, Sawara K, Takikawa Y, Suzuki K,. Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results. Hepatol Res. 2009; 39: 117-125.
16. Kasai K, Ushio A, Kasai Y, et al. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma. Int J Clin Oncol. 2011; 16: 221-229.
17. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer [in Japanese]. 4th ed. Tokyo, Japan: Kanehara; 2000.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. Available at: Accessed on September 1, 2006.
20. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100: 698-711.
21. Chen SC, Hsieh MY, Chuang WL, Wang LY, Chang WY,. Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol. 1994; 9: 1-6.
22. Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol. 1993; 23: 105-109.
23. Tanaka A, Morimoto T, Yamaoka Y,. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology. 1996; 43: 637-643. (Pubitemid 26190123)
24. Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci. 2007; 52: 3290-3295. (Pubitemid 47512562)
25. Chung JW, Park JH, Han JK, Choi BI, Han MC,. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol. 1995; 165: 315-321.
26. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY,. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer. 1997; 79: 2087-2094. (Pubitemid 27227372)
27. Breedis C, Young G,. The blood supply of neoplasms in the liver. Am J Pathol. 1954; 30: 969-977.
28. Ando E, Yamashita F, Tanaka M, Tanikawa K,. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer. 1997; 79: 1890-1896. (Pubitemid 27200371)
29. Itamoto T, Nakahara H, Tashiro H, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol. 2002; 80: 143-148. (Pubitemid 34747619)
30. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S,. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun. 1992; 182: 1232-1239.
31. Elias L, Sandoval JM,. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun. 1989; 163: 867-874. (Pubitemid 19236930)
32. Wadler S, Schwartz EL,. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990; 50: 3473-3486. (Pubitemid 20194083)
33. Brinkmann V, Geiger T, Alkan S, Heusser CH,. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993; 178: 1655-1663. (Pubitemid 23318444)
34. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S,. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology. 2001; 33: 346-356. (Pubitemid 32119024)
35. Ortaldo JR, Mantovani A, Hobbs D, Rubinstein M, Pestka S, Herberman RB,. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer. 1983; 31: 285-289. (Pubitemid 13110600)
36. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003; 424: 516-523. (Pubitemid 36975769)
37. Uno K, Shimizu S, Ido M, et al. Direct and indirect effects of interferon on in vivo murine tumor cell growth. Cancer Res. 1985; 45: 1320-1327. (Pubitemid 15111299)
38. Kondo M, Nagano H, Wada H, et al. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res. 2005; 11: 1277-1286. (Pubitemid 40175781)
39. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF,. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 2000; 39: 10634-10640.
40. Yano H, Iemura A, Haramaki M, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology. 1999; 29: 1708-1717. (Pubitemid 29247043)
41. Drewinko B, Yang LY,. Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep. 1985; 69: 1391-1398. (Pubitemid 16163078)
42. Guchelaar HJ, Vermes I, Koopmans RP, Reutelingsperger CP, Haanen C,. Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol. 1998; 42: 77-83. (Pubitemid 28224995)
43. Ueshima K, Tatsumi C, Sakagucih Y, Minami Y, Tei H, Fukunaga T,. Breakthrough of the hepatic arterial infusion chemotherapy of hepatocellular carcinoma. Gastroenterology (Tokyo). 2006; 43: 253-259.
44. Nagamatsu H, Hiraki M, Mizukami N, et al. Intra-arterial therapy with cisplatin suspension in Lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther. 2010; 32: 543-550.